Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Maturity of Maturity Models in Health Care and Informatics.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same author

Engaging Arab/MENA Communities in Learning Health Systems: Insights and Guidance for Future Research on AI and Health Equity.

Learning health systems·2026
Same author

Patient Perceptions and preferences for the disclosure of artificial intelligence generated draft replies to electronic messages - A qualitative study.

International journal of medical informatics·2026
Same author

The Potential for a Benefit-Estimating Algorithm to Improve Recommendations for Preventive Services: Comparing Algorithm Recommendations with Those of Primary Care Providers.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same author

Assessment of the adequacy of the Fast Healthcare Interoperability Resources (FHIR) Genomics standard for the representation of somatic testing reports.

JAMIA open·2026
Same author

Community perspectives on health AI: hopes, concerns and implications for health systems and trustworthy AI.

AI and ethics·2026

相关实验视频

Updated: Jul 2, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K

提前成熟度建模用于精密瘤学.

Ariella Hoffman-Peterson1, Megh Marathe2, Mark S Ackerman1

  • 1University of Michigan, Ann Arbor, MI, USA.

Journal of clinical and translational science
|February 22, 2024
PubMed
概括

精确瘤学的成熟度目前很低,但在不断发展. 推进这种学习健康系统需要了解复杂的基础设施需求,并关闭学习循环,以获得更好的癌症护理.

关键词:
精确瘤学是一门精确的专业.学习周期的学习周期.学习健康系统学习健康系统期限模型的到期期期模型.分子瘤板分子瘤板.

更多相关视频

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

相关实验视频

Last Updated: Jul 2, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

科学领域:

  • 在瘤学瘤学.
  • 卫生系统科学 卫生系统科学
  • 生物信息学是一种生物信息学.

背景情况:

  • 精密瘤学旨在为个别患者量身定制癌症治疗.
  • 学习健康系统 (LHS) 将证据纳入实践.
  • 将精确瘤学的成熟度绘制为LHS对其进步至关重要.

研究的目的:

  • 评估精准瘤学作为学习健康系统的成熟度.
  • 了解当前的实践状态,工具,信息学,障碍和促进者.
  • 确定提高现场成熟度的策略.

主要方法:

  • 与学术医疗中心和下一代测序公司的34名专业人士进行了半结构化采访.
  • 受访者包括临床医生,病理学家和参与分子瘤委员会 (MTBs) 的项目经理.
  • 分析了采访数据,以了解精密瘤学的成熟度变化.

主要成果:

  • 精确瘤学的成熟度目前很低,但在实践,工具和信息学中不断发展.
  • 资源密集和复杂的社会技术基础设施是影响成熟度的关键因素.
  • 关闭学习循环对于推进该领域至关重要.

结论:

  • 该研究定义并将精确瘤学的当前成熟度置于背景.
  • 为检查LHS成熟度和开发成熟度模型提供了一个框架.
  • 为推进精确瘤学的未来战略提供了见解.